Form 4: Travere CMO Sells Shares Under 10b5-1 Plan

Travere Therapeutics' Chief Medical Officer, Jula Inrig, sold common stock on February 4, 2026, under a pre-arranged 10b5-1 plan, including shares to cover tax obligations from vested restricted stock units.

Summary

• Jula Inrig, Chief Medical Officer of Travere Therapeutics, Inc. (TVTX), reported the sale of common stock.
• The transactions occurred on February 4, 2026.
• A total of 1,547 shares were sold at a weighted average price of $32.11 per share, with prices ranging from $31.65 to $32.61.
• An additional 232 shares were sold at a weighted average price of $32.85 per share, with prices ranging from $32.80 to $32.90.
• These sales were executed pursuant to a written plan adopted on May 28, 2025, which meets the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934.
• The sales included shares designated to cover tax obligations arising from the vesting of restricted stock units.
• Following these transactions, Jula Inrig beneficially owns 105,706 shares of Travere Therapeutics common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the insider sale was pre-scheduled under a 10b5-1 plan and primarily for tax purposes related to RSU vesting, rather than a discretionary sale indicating a change in outlook.

Negatives

• The sale of shares by an insider, even for tax purposes, could be perceived by some investors as a slight negative, though mitigated by the pre-arranged 10b5-1 plan and tax obligation context.

Future Outlook

N/A

Management Comments

• The sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
• The sale includes shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that insider sales under Rule 10b5-1 plans, particularly those designed to cover tax obligations arising from the vesting of restricted stock units, are a common and routine practice among executives in the biotechnology and pharmaceutical sectors. These pre-arranged plans allow insiders to manage their equity compensation in a compliant manner, mitigating concerns about trading on material non-public information.

Comparison to Industry Standards

• This transaction is consistent with standard insider compensation practices across the biotechnology and pharmaceutical industries, where executives often sell a portion of vested equity to cover tax liabilities.

Stakeholder Impact

• Shareholders: The transaction represents a routine insider sale for tax purposes and is unlikely to have a significant impact on shareholder perception or the company's stock price.

Key Dates

Recommendation

The filing details a routine insider stock sale by the Chief Medical Officer under a pre-arranged 10b5-1 plan, primarily to cover tax obligations from vested restricted stock units. This type of transaction is common and does not typically signal a change in the company's fundamental outlook or warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing provides no new information to alter an existing investment thesis.

Keywords

Travere Therapeutics, TVTX, Insider Trading, Form 4, Stock Sale, Jula Inrig, Chief Medical Officer, 10b5-1 Plan, Restricted Stock Units, Tax Obligation